Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Chawla

Showing results (161-170 of 171) with videos related to

Pageof 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2022
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid TumorsGeorge D Demetri, Filippo De Braud, Alexander Drilon, et al.
Lancet (London, England)|May 19, 2012
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialWinette T A van der Graaf, Jean-Yves Blay, Sant P Chawla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2021
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid TumorsAntje Wick, Oliver Bähr, Martin Schuler, et al.
The Lancet. Oncology|April 1, 2020
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trialJosé Trigo, Vivek Subbiah, Benjamin Besse, et al.
The Lancet. Oncology|June 28, 2017
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trialWilliam D Tap, Zsuzsanna Papai, Brian A Van Tine, et al.
Lung Cancer (Amsterdam, Netherlands)|October 23, 2020
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatmentVivek Subbiah, Luis Paz-Ares, Benjamin Besse, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trialsRobert C Doebele, Alexander Drilon, Luis Paz-Ares, et al.
Cancer Research Communications|November 18, 2025
Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor PatientsVivek Subbiah, Peter P Yu, Rangaprasad Sarangarajan, et al.
Nature Communications|June 15, 2022
Clinical genomic profiling in the management of patients with soft tissue and bone sarcomaMrinal M Gounder, Narasimhan P Agaram, Sally E Trabucco, et al.
Nature|January 8, 2020
A repeating fast radio burst source localized to a nearby spiral galaxyB Marcote, K Nimmo, J W T Hessels, et al.
Pageof 18

Showing results (161-170 of 171) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2022
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid TumorsGeorge D Demetri, Filippo De Braud, Alexander Drilon, et al.
Lancet (London, England)|May 19, 2012
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialWinette T A van der Graaf, Jean-Yves Blay, Sant P Chawla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2021
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid TumorsAntje Wick, Oliver Bähr, Martin Schuler, et al.
The Lancet. Oncology|April 1, 2020
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trialJosé Trigo, Vivek Subbiah, Benjamin Besse, et al.
The Lancet. Oncology|June 28, 2017
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trialWilliam D Tap, Zsuzsanna Papai, Brian A Van Tine, et al.
Lung Cancer (Amsterdam, Netherlands)|October 23, 2020
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatmentVivek Subbiah, Luis Paz-Ares, Benjamin Besse, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trialsRobert C Doebele, Alexander Drilon, Luis Paz-Ares, et al.
Cancer Research Communications|November 18, 2025
Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor PatientsVivek Subbiah, Peter P Yu, Rangaprasad Sarangarajan, et al.
Nature Communications|June 15, 2022
Clinical genomic profiling in the management of patients with soft tissue and bone sarcomaMrinal M Gounder, Narasimhan P Agaram, Sally E Trabucco, et al.
Nature|January 8, 2020
A repeating fast radio burst source localized to a nearby spiral galaxyB Marcote, K Nimmo, J W T Hessels, et al.
Pageof 18